Aurigene Pharmaceutical Services, the integrated drug discovery and CDMO arm of Dr. Reddy’s Laboratories, has announced progress in its research collaboration with Alveus Therapeutics, marking the nomination of ALV-200 as the first development candidate under their partnership focused on obesity and metabolic disorders.

The collaboration combines Alveus’ expertise in metabolic biology and therapeutic strategy with Aurigene’s integrated discovery capabilities spanning computational design, medicinal chemistry and biology platforms.

As part of the partnership, the companies have advanced ALV-200, a highly selective AMYR3 peptide candidate, positioned within Alveus’ next-generation pipeline for obesity and metabolic diseases.

Aurigene said multiple additional discovery programmes are also progressing under the alliance, supporting Alveus’ expanding research portfolio in metabolic disorders, one of the fastest-growing therapy segments globally amid rising obesity prevalence.

A key enabler of the programme has been Aurigene.AI, the company’s AI-driven drug discovery platform that integrates generative molecular design, predictive modelling and computational chemistry with high-throughput lab workflows to accelerate design-make-test cycles and candidate optimisation.

“This collaboration reflects Aurigene’s ability to support innovative biotechnology companies with integrated discovery capabilities across computational and experimental platforms,” said Akhil Ravi, Chief Executive Officer at Aurigene Pharmaceutical Services. “We are pleased to contribute our expertise to programs aimed at addressing important unmet needs in metabolic disease.”

“We selected Aurigene for their strong discovery capabilities and integrated platform supporting peptide and small molecule research,” said Jacob Jeppesen, Chief Scientific Officer and Head of R&D at Alveus Therapeutics. “Their team has been an important contributor to advancing several of our discovery programs, including the nomination of ALV-200.”